Bilirubin: An Endogenous Inducer of Nrf2 Pathway and Its Possible Application in Therapy

Mohammed Qaisiya*

Hebron University, Hebron

Submission: July 01, 2017; Published: August 04, 2017

*Corresponding author: Mohammed Qaisiya, Hebron University, West bank-Palestine. P.O Box 40, Hebron, Tel: 00970-2-2220995; Email: qaisiyam@hebron.edu

Commentary

It has been asked, why convert-in a step that consumes energy-biliverdin a non-toxic easily excretable waste product, into bilirubin, that is unexcretable, neurotoxic, and has to be further metabolized for dispose? These two pages opinion focus on the possible effects of bilirubin on an important cyto-protective pathway named Nrf2 antioxidant signaling. In animals, the end product of oxidative degradation of heme results in a yellow pigment named un-conjugated bilirubin (UCB) that has a significant importance role during physiological and pathological conditions. UCB once produced is transferred into liver and then conjugated with glucuronic acid by the enzyme UGT1A1. UCB is responsible for neonatal jaundice that occurs in most newborn during the first week of life [1,2]. However, UCB is a potential neurotoxic and in very few cases, such as Crigler Najjar syndrome type I in which the activity of UGT1A1 is completely absent; UCB leads to neurotoxicity or kernicterus [3].

UCB plays a major role as a significant antioxidant at physiological levels, although we are still far from a complete understanding of this phenomenon. The antioxidant ability of UCB arises from a popular explanation of redox consuming cycling mechanism that act between the conversions of UCB in biliverdin. Several in vitro studies support the “direct” antioxidant properties of UCB [2,4]. Support for an in vivo antioxidant capacity of bilirubin is mainly “indirect evidences”. The modest elevations of the plasma UCB in neonates are suggested by acting as a direct potent antioxidant [5]. Similarly, in Gilbert syndrome, the mild hyperbilirubinemia is negatively related to the risk of different diseases associated with oxidative stress such as atherosclerosis and cancer [6,7]. Gilbert syndrome is a very common chronic, mild hyperbilirubinemia (total serum bilirubin around 5mg/dl), mainly due to a recessive insertional mutation in TATAAA box of UGT1A1 gene. Such mutations resulting in a reduced UGT1A1-activity to about 30% of normal [8]. UCB also possess antioxidant properties in Gunn rat (animal model of Crigler Najjar syndrome type I) [9]. In a recent study, mice have been treated with UCB and showed anti-obesity and anti-diabetic effects. UCB reduces cholesterol, improve insulin resistance and glucose tolerance and authors suggest UCB treatment or use of partial UGT1A1 inhibitors as a possible therapeutic approach to treat metabolic disorders [10].

Since UCB induced cyto-toxicity is specific for certain types of neurons (e.g., Purkinjie) and occurred at a very high level of UCB, it is suggested that organs that possess resistance to UCB toxicity such as liver benefit from the “direct” antioxidant properties of UCB, based on the popular model of Baranano et al. [4]. However, further investigations are needed to clarify this direct antioxidant properties of bilirubin, since another more recent study demonstrated a limited role for bilirubin-biliverdin redox cycle in the cellular antioxidant protection [11]. We reported the indirect effects of UCB toward the activation of the master regulator of the endogenous antioxidant system called Nrf2 pathway [12]. Nrf2 transcription factor is tethered within the cytosol by inhibitory partner called Keap-1. Once activated, Nrf2 undergo a conformational change resulting in a translocation of Nrf2 to nucleus and binds to antioxidant response element (ARE), an enhancer sequence presents in the promoter of a wide array of cyto-protective genes. Nrf2 regulates plethora of genes called “Nrf2 gene battery” include genes involved in glutathione homeostasis, NADPH utilization, heme-oxygenase I and quinone oxidoreductase 1 signaling, sulfonyl-transfases, peroxiredoxine, thioredoxine, superoxide dismutase 1, catalase, ABC efflux transporters and many others [13-16].

The coordinated induction of Nrf2 target genes represents a potential therapeutic strategy to overcome several diseases [17]. Interestingly, a novel strategy for reducing oxidative stress-
associated diseases in vivo (cardiovascular disease, cancer, and inflammatory syndromes) was suggested by increasing serum UCB level. Our previous interesting results demonstrated Nrf2 pathway activation by hyperbilirubinemia, indicating that UCB is a potential endogenous compound that activate Nrf2 pathway. This may represent a positive response to the pro-oxidant concentration of UCB in the organs that are able to tolerate UCB toxicity such as liver, by activating cellular antioxidant system through Nrf2 and providing cell protection against toxic insults. It could be possible that the whole cyto-protection effects under elevated hyperbilirubinemia are mainly related to the activation of Nrf2 pathway. According to this hypothesis, it will be interesting to study Nrf2 pathway activation in animals and subjects with hyperbilirubinemia especially in Gilbert syndrome and its possible application in therapy as a potent inducer for Nrf2 signaling. Further studies are needed to confirm or confute this hypothesis.

Reference

1. Denney P A, Sedman DS, Stevenson DK (2001) Neonatal hyperbilirubinemia N Engl J Med 344(8): 581-590.
2. Sedlak TW, Snyder SH (2004) Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics 113(6): 1776-1782.
3. Watchko JF (2006) Kernicterus and the molecular mechanisms of bilirubin-induced CNS injury in newborns. Neuromolecular Med 8(4): 513-529.
4. Baranano DE, Rao M, Ferris CD, Snyder SH (2002) Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci 99(25): 16093-16098.
5. Bélanger S, Lavoie JC, Chessex P (1997) Influence of bilirubin on the antioxidant capacity of plasma in newborn infants. Biol Neonate 71(4): 233-238.
6. Rigato I, Ostrow JD, Tiriell C (2005) Bilirubin and the risk of common non-hepatic diseases. Trends Mol Med 11(6): 277-283.
7. Vítek L, Novotný L, Sperl M, Holaj R, Spácil J (2006) The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis 21: 408-414.
8. Hirschfield GM, Alexander GJ (2006) Gilbert’s syndrome: an overview for clinical biochemists. Ann Clin Biochem 43(Pt 5): 340-343.
9. Denney PA, McDonagh, AF, Spitz DR, Rodgers PA, Stevenson DK (1995) Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia. Free Radic Biol Med 19(4): 395-404.
10. Liu J, Dong H, Zhang Y, Cao M, Song L, et al. (2015) Bilirubin Increases Insulin Sensitivity by Regulating Cholesterol Metabolism, Adipokines and PPARγ. Levels Sci Rep 5: 9886.
11. Maghzal GJ, Lock MC, Collinson E, Li C, Stocker R (2009) Limited role for the bilirubin-biliverdin redox amplification cycle in the cellular antioxidant protection by biliverdin reductase. J Biol Chem 284(43): 29251-29259.
12. Qaisiya M, Coda ZCD, Bellarosa C, Tiriell C (2014) Bilirubin mediated oxidative stress involves antioxidant response activation via Nrf2 pathway Cell Signal 26(3): 512-520.
13. Hayes JD, Dinkova KAT (2014) The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 39(4): 199-218.
14. Malhotra D, Portales CE, Singh A, Srivastava S, Arenillas D, et al. (2010) Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 38(17): 5718-5734.
15. Gorrini C, Harris IS, Mak TW (2013) Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12(12): 931-947.
16. Calkins MJ, Johnson DA, Townsend JA, Vargas MR, Dowell JA, et al. (2009) The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Anitoxid Redox Signal 11(3): 497-508.
17. Jung KA, Kwak MK (2010) The Nrf2 system as a potential target for the development of indirect antioxidants. Mol Basel Switz 15(10): 7266-7291.
18. McCarty MF (2007) Iatrogenic Gilbert syndrome—a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses 69(5): 974-994.
19. Kim SD, Anteno M, Squires EJ, Kirby GM (2013) Cytochrome P450 2A5 and bilirubin: mechanisms of gene regulation and cytoprotection. Toxicol Appl Pharmacol 270(2): 129-138.